


ベトナムにおける遺伝性血管性浮腫の診断方法の確立・治療の強化、ガイドライン策定の支援事業

【背景】

- ベトナムにおけるHAEの疾患認知度は極めて低く、検査・診断技法も確立されておらず、治療の中核拠点や治療のガイドラインも整備されていなかった。3年間の当事業を通じてガイドラインや疾患啓発資材を作成し、医療関係者ならびに市民・患者への疾患啓発ができたことから19例の確定診断には至ったものの、推定患者数の1%にとどまり、診療医や診療中核拠点病院は限定的である。2024年には新規治療薬の承認が予定されていることから、ベトナムの学会・医師はより広い地域・診療科において診療医・中核拠点病院を作る必要があると考えている。

【事業目的・事業概要】（日本の武田薬品が実施主体）

- 初年度（令和3年度）：ベトナムの医療従事者に対する疾患啓発と能力強化、現地版HAE診療ガイドラインの策定開始
- 二年目（令和4年度）：検査・診断技法の確立、現地版HAE診療ガイドラインの策定、市民・患者への疾患啓発、中核拠点（Center of Excellence: CoE）構築とフォローアップ体制整備に関する検討開始
- 三年目（令和5年度）：現地版HAEガイドラインの普及、市民・患者への疾患啓発、CoE構築（ホーチミン、ハノイ、カントー）
- 四年目（令和6年度）**：ホーチミン・ハノイ・カントー以外のエリアも含めた診療医・CoE拡大、医療機関間のネットワーク構築、市民・患者への更なる疾患啓発、新規HAE治療薬による治療の開始




Project on establishing diagnostic methods, strengthening treatment, and developing guidelines for hereditary angioedema in Vietnam

[BACKGROUND]

- The disease awareness of HAE in Vietnam was extremely low, and testing/diagnostic techniques have not been established, and core sites of treatment and treatment guidelines had not been prepared. Through this program for 3 years, we prepared the guidelines and disease awareness materials, and raised disease awareness among healthcare professionals, citizens, and patients. As a result, 19 patients were finally diagnosed, but the number of diagnosed patients is only 1% of the estimated number of potential patients and the number of doctors and hospitals for HAE treatment are still very limited. Since a new drug for treatment of acute attacks is planned to be approved in 2024, the Vietnamese academic society and physicians consider that it's necessary to educate more medical doctors and establish more key hospitals for HAE treatment.

[PROJECT OVERVIEW]

- Year 1 (2021): Raise awareness of HAE and strengthen the capacity of Vietnamese healthcare professionals and begin formulating local HAE treatment guidelines.
- Year 2 (2022): Establish testing and diagnostic techniques, formulate local HAE treatment guidelines, raise awareness of the disease among Vietnamese citizens, and begin discussions on establishing Center of Excellence (CoE) and follow-up system.
- Year 3 (2023): Disseminate the local guidelines, raise the disease awareness and establish CoEs in Ho Chi, Hanoi and Can Tho.
- Year 4(2024): Educate more physicians and build more CoEs in the areas besides Ho Chi Minh, Hanoi and Can Tho, strengthen network among CoEs, raise disease awareness and deliver a new HAE drug to patients.



- A. August 2024-January 2025
Education&Training (On-site and Web)
- B. August - October 2024
Spread the new guideline (On-site and Web)
- C. November 2024
Support establishment of CoE and the network (On-site)
- D. June 2024-January 2025
Disease awareness • patient education (On-site and Web)
- E. June 2024 • January 2025
Project management meetings (On-site and Web)